Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
1.000 | 0.080 | 12 | 68808017 | upstream gene variant | C/G | snv | 0.56 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
0.882 | 0.040 | 12 | 68828867 | stop lost | T/G | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||||
|
0.882 | 0.040 | 12 | 68828867 | stop lost | T/G | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||||
|
0.882 | 0.040 | 12 | 68828867 | stop lost | T/G | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||||
|
1.000 | 0.120 | 12 | 68839310 | frameshift variant | C/-;CC | delins |
|
Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||||
|
0.882 | 0.040 | 12 | 68841626 | 3 prime UTR variant | G/A | snv | 0.35 |
|
Neoplasms | 0.020 | 0.500 | 2 | 2014 | 2016 | |||||||
|
0.882 | 0.040 | 12 | 68841626 | 3 prime UTR variant | G/A | snv | 0.35 |
|
Neoplasms | 0.020 | 0.500 | 2 | 2014 | 2016 | |||||||
|
0.882 | 0.040 | 12 | 68841626 | 3 prime UTR variant | G/A | snv | 0.35 |
|
Neoplasms | 0.020 | 0.500 | 2 | 2014 | 2016 | |||||||
|
0.882 | 0.040 | 12 | 68841626 | 3 prime UTR variant | G/A | snv | 0.35 |
|
Neoplasms; Musculoskeletal Diseases | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||||
|
12 | 68847050 | 3 prime UTR variant | A/G | snv | 0.34 |
|
0.700 | 1.000 | 1 | 2019 | 2019 | ||||||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms | 0.030 | 1.000 | 3 | 2016 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms | 0.030 | 1.000 | 3 | 2016 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms; Eye Diseases | 0.030 | 1.000 | 3 | 2016 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
0.010 | 1.000 | 1 | 2016 | 2016 | ||||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Digestive System Diseases; Neoplasms | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Digestive System Diseases; Neoplasms | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Digestive System Diseases; Neoplasms | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms; Respiratory Tract Diseases | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Digestive System Diseases; Neoplasms | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.716 | 0.200 | 12 | 68808384 | 5 prime UTR variant | A/G | snv | 0.37 |
|
Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases | 0.010 | 1.000 | 1 | 2015 | 2015 |